Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer

Radiation Research

Volumn 170, Issue 1, 2008, Pages 49-59

  Burri, Ryan J ^a   Stock, Richard G ^a   Cesaretti, Jamie A ^a   Atencio, David P ^a   Peters, Sheila ^a   Peters, Christopher A ^a   Fan, Grace ^a   Stone, Nelson N ^a   Ostrer, Harry ^b   Rosenstein, Barry S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DISEASE PREDISPOSITION; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; RECTUM HEMORRHAGE; SINGLE NUCLEOTIDE POLYMORPHISM; SOD2 GENE; URINARY TRACT DISEASE; XRCC1 GENE; XRCC3 GENE;

AGED; DNA-BINDING PROTEINS; ERECTILE DYSFUNCTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY; RECTAL DISEASES; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 46449108180     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1219.1     Document Type: Article

References (81)

1. R. S. Herbst and S. M. Lippman, Molecular signatures of lung cancer - Toward personalized therapy. N. Engl. J. Med. 356, 76-78 (2007).
2. E. J. Hall, P. B. Schiff, G. E. Hanks, D. J. Brenner, J. Russo, J. Chen, S. G. Sawant and T. K. Pandita, A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J. Sci. Am. 4, 385-389 (1998).
3. C. N. Andreassen, J. Alsner, M. Overgaard and J. Overgaard, Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69, 127-135 (2003).
4. M. Fernet and J. Hall, Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst.) 3, 1237-1243 (2004).
5. J. A. Cesaretti, R. G. Stock, S. Lehrer, D. P. Atencio, J. L. Bernstein, N. N. Stone, S. Wallenstein, S. Green, K. Loeb and B. S. Rosenstein, ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 61, 196-202 (2005).
6. C. N. Andreassen, J. Alsner, J. Overgaard, C. Herskind, J. Haviland, R. Owen, J. Homewood, J. Bliss and J. Yarnold, TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother. Oncol. 75, 18-21 (2005).
7. J. Chang-Claude, O. Popanda, X. L. Tan, S. Kropp, I. Helmbold, D. von Fournier, W. Haase, M. L. Sautter-Bihl, F. Wenz and C. B. Ambrosone, Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin. Cancer Res. 11, 4802-4809 (2005).
8. J. Rzeszowska-Wolny, J. Polanska, M. Pietrowska, O. Palyvoda, J. Jaworska, D. Butkiewicz and R. Hancock, Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat. Res. 164, 132-140 (2005).
9. T. Takanami, J. Nakamura, Y. Kubota and S. Horiuchi, The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability. Mutat. Res. 582, 135-145 (2005).
10. K. De Ruyck, M. Van Eijkeren, K. Claes, R. Morthier, A. De Paepe, A. Vral, L. De Ridder and H. Thierens, Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int. J. Radiat. Oncol. Biol. Phys. 62, 1140-1149 (2005).
11. K. De Ruyck, C. S. Wilding, M. Van Eijkeren, R. Morthier, E. J. Tawn and H. Thierens, Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence. Radiat. Res. 164, 237-244 (2005).
12. C. N. Andreassen, J. Alsner, M. Overgaard, F. B. Sorensen and J. Overgaard, Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM - a study based on DNA from formalin fixed paraffin embedded tissue samples. Int. J. Radiat. Biol. 82, 577-586 (2006).
13. S. Damaraju, D. Murray, J. Dufour, D. Carandang, S. Myrehaug, G. Fallone, C. Field, R. Greiner, J. Hanson and M. Parliament, Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin. Cancer Res. 12, 2545-2554 (2006).
14. O. Popanda, X. L. Tan, C. B. Ambrosone, S. Kropp, I. Helmbold, D. von Fournier, W. Haase, M. L. Sautter-Bihl, F. Wenz and J. Chang-Claude, Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 15, 1048-1050 (2006).
15. G. Alsbeih, M. El-Sebaie, N. Al-Harbi, M. Al-Buhairi, K. Al-Hadyan and N. Al-Rajhi, Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int. J. Radiat. Oncol. Biol. Phys. 68, 229-235 (2007).
16. G. Giotopoulos, R. P. Symonds, K. Foweraker, M. Griffin, I. Peat, A. Osman and M. Plumb, The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br. J. Cancer 96, 1001-1007 (2007).
17. J. A. Cesaretti, R. G. Stock, D. P. Atencio, S. Peters, C. A. Peters, R. J. Burri, N. N. Stone and B. S. Rosenstein, A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 68, 1410-1416 (2007).
18. C. A. Peters, R. G. Stock, J. A. Cesaretti, D. P. Atencio, S. Peters, R. J. Burri, N. N. Stone, H. Ostrer and B. S. Rosenstein, TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70, 752-759 (2008).
19. R. G. Stock, N. N. Stone, M. F. Wesson and J. K. DeWyngaert, A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 32, 219-225 (1995).
20. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson and A. S. Meigooni, Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med. Phys. 22, 209-234 (1995).
21. R. G. Stock, N. N. Stone, J. A. Cesaretti and B. S. Rosenstein, Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int. J. Radiat. Oncol. Biol. Phys. 64, 527-533 (2006).
22. J. D. Cox, J. Stetz and T. F. Pajak, Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31, 1341-1346 (1995).
23. M. J. Barry, F. J. Fowler, Jr., M. P. O'Leary, R. C. Bruskewitz, H. L. Holtgrewe, W. K. Mebust and A. T. Cockett, The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 148, 1549-1557; discussion 1564 (1992).
24. R. G. Stock, J. Kao and N. N. Stone, Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J. Urol. 165, 436-439 (2001).
25. R. G. Stock, N. N. Stone and C. Iannuzzi, Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 35, 267-272 (1996).
26. D. P. Atencio, C. M. Iannuzzi, S. Green, R. G. Stock, J. L. Bernstein and B. S. Rosenstein, Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environ. Mol. Mutagen. 38, 200-208 (2001).
27. S. Rozen and H. J. Skaletsky, Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols: Methods in Molecular Biology (S. Krawetz and S. Misener, Eds.), pp. 365-386. Humana Press, Totowa, NJ, 2000. [Article available online at http://jura.wi.mit.edu/ rozen/papers/rozen-and-skaletsky-2000-primer3.pdf; source code available at http://primer3.sourceforge.net/].
28. D. J. Brenner and E. J. Hall, Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43, 1095-1101 (1999).
29. D. J. Brenner, A. A. Martinez, G. K. Edmundson, C. Mitchell, H. D. Thames and E. P. Armour, Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β- ratio) comparable to late-responding normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 52, 6-13 (2002).
30. J. Z. Wang, M. Guerrero and X. A. Li, How low is the α/β- ratio for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 55, 194-203 (2003).
31. J. F. Fowler, M. A. Ritter, R. J. Chappell and D. J. Brenner, What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56, 1093-1104 (2003).
32. D. J. Brenner, Hypofractionation for prostate cancer radiotherapy - what are the issues? Int. J. Radiat. Oncol. Biol. Phys. 57, 912-914 (2003).
33. J. C. Barrett, B. Fry, J. Maller and M. J. Daly, Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
34. 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int. J. Radiat. Oncol. Biol. Phys. 50, 335-341 (2001).
35. M. J. Zelefsky, Z. Fuks, M. Hunt, Y. Yamada, C. Marion, C. C. Ling, H. Amols, E. S. Venkatraman and S. A. Leibel, High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 53, 1111-1116 (2002).
36. R. G. Stock, N. N. Stone, A. Tabert, C. Iannuzzi and J. K. De-Wyngaert, A dose-response study for I-125 prostate implants. Int. J. Radiat. Oncol. Biol. Phys. 41, 101-108 (1998).
37. A. Pollack, G. K. Zagars, G. Starkschall, J. A. Antolak, J. J. Lee, E. Huang, A. C. von Eschenbach, D. A. Kuban and I. Rosen, Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097-1105 (2002).
38. A. Pollack, A. L. Hanlon, E. M. Horwitz, S. J. Feigenberg, R. G. Uzzo and G. E. Hanks, Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J. Urol. 171, 1132-1136 (2004).
39. P. A. Kupelian, M. Elshaikh, C. A. Reddy, C. Zippe and E. A. Klein, Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol. 20, 3376-3385 (2002).
40. M. Han, A. W. Partin, C. R. Pound, J. I. Epstein and P. C. Walsh, Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28, 555-565 (2001).
41. F. J. Bianco, Jr., P. T. Scardino and J. A. Eastham, Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 66, 83-94 (2005).
42. G. S. Merrick, W. M. Butler, R. W. Galbreath, R. L. Stipetich, L. J. Abel and J. H. Lief, Erectile function after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 52, 893-902 (2002).
43. J. A. Cesaretti, J. Kao, N. N. Stone and R. G. Stock, Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at ≥ 7 years of follow-up. BJU Int. 100, 362-367 (2007).
44. Breast Cancer Association Consortium, Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J. Natl. Cancer Inst. 98, 1382-1396 (2006).
45. S. S. Wang, S. Davis, J. R. Cerhan, P. Hartge, R. K. Severson, W. Cozen, Q. Lan, R. Welch, S. J. Chanock and N. Rothman, Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis 27, 1828-1834 (2006).
46. Q. Lan, T. Zheng, M. Shen, Y. Zhang, S. S. Wang, S. H. Zahm, T. R. Holford, B. Leaderer, P. Boyle and S. Chanock, Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum. Genet. 121, 161-168 (2007).
47. M. Udler, A. T. Maia, A. Cebrian, C. Brown, D. Greenberg, M. Shah, C. Caldas, A. Dunning, D. Easton and P. Pharoah, Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J. Clin. Oncol. 25, 3015-3023 (2007).
48. A. Sutton, H. Khoury, C. Prip-Buus, C. Cepanec, D. Pessayre and F. Degoul, The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria, Pharmacogenetics 13, 145-157 (2003).
49. A. Sutton, A. Imbert, A. Igoudjil, V. Descatoire, S. Cazanave, D. Pessayre and F. Degoul, The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenetics 15, 311-319 (2005).
50. S. L. Winsey, N. A. Haldar, H. P. Marsh, M. Bunce, S. E. Marshall, A. L. Harris, F. Wojnarowska and K. I. Welsh, A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 60, 5612-5616 (2000).
51. B. Kuschel, A. Auranen, S. McBride, K. L. Novik, A. Antoniou, J. M. Lipscombe, N. E. Day, D. F. Easton, B. A. Ponder and A. Dunning, Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11, 1399-1407 (2002).
52. N. R. Jacobsen, O. Raaschou-Nielsen, B. Nexø, H. Wallin, K. Overvad, A. Tjønneland and U. Vogel, XRCC3 polymorphisms and risk of lung cancer. Cancer Lett. 213, 67-72 (2004).
53. C. Seedhouse, R. Faulkner, N. Ashraf, E. Das-Gupta and N. Russell, Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia, Clin. Cancer Res. 10, 2675-2680 (2004).
54. I. Dianzani, L. Gibello, A. Biava, M. Giordano, M. Bertolotti, M. Betti, D. Ferrante, S. Guarrera, G. P. Betta and C. Magnani, Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat. Res. 599, 124-134 (2006).
55. K. E. Smedby, C. M. Lindgren, H. Hjalgrim, K. Humphreys, C. Schöllkopf, E. T. Chang, G. Roos, L. P. Ryder, K. I. Falk and H. O. Adami, Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol. Biomarkers Prev. 15, 258-265 (2006).
56. J. D. Figueroa, N. Malats, F. X. Real, D. Silverman, M. Kogevinas, S. Chanock, R. Welch, M. Dosemeci, A. Tardón and M. García-Closas, Genetic variation in the base excision repair pathway and bladder cancer risk. Hum. Genet. 121, 233-242 (2007).
57. N. R. Jacobsen, B. A. Nexø, A. Olsen, K. Overvad, H. Wallin, A. Tjønneland and U. Vogel, No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer. Cancer Epidemiol. Biomarkers Prev. 12, 584-585 (2003).
58. M. C. Stern, K. Conway, Y. Li, K. Mistry and J. A. Taylor, DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol. Carcinog. 45, 715-719 (2006).
59. N. Liu, J. E. Lamerdin, R. S. Tebbs, D. Schild, J. D. Tucker, M. R. Shen, K. W. Brookman, M. J. Sciliano, C. A. Walter and L. H. Thompson, XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA crosslinks and other damages. Mol. Cell. 1, 783-793 (1998).
60. M. A. Brenneman, B. M. Wagener, C. A. Miller, C. Allen and J. A. Nickoloff, XRCC3 controls the fidelity of homologous recombination: roles for XRCC3 in late stages of recombination. Mol. Cell. 10, 387-395 (2002).
61. F. D. Araujo, A. J. Pierce, J. M. Stark and M. Jasin, Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 21, 4176-4180 (2002).
62. T. Yoshihara, M. Ishida, A. Kinomura, M. Katsura, T. Tsuruga, S. Tashiro, T. Asahara and K. Miyagawa, XRCC3 deficiency results in a defect in recombination and increased endoreduplication in human cells. EMBO J. 23, 670-680 (2004).
63. C. S. Wilding, G. B. Curwen, E. J. Tawn, X. Sheng, J. F. Winther, R. Chakraborty and J. D. Boice, Jr., Influence of polymorphisms at loci encoding DNA repair proteins on cancer susceptibility and G2 chromosomal radiosensitivity. Environ. Mol. Mutagen. 48, 48-57 (2007).
64. R. A. Mateuca, M. Roelants, G. Iarmarcovai, P. V. Aka, L. Godderis, A. Tremp, S. Bonassi, M. Fenech, J. L. Bergé-Lefranc and M. Kirsch-Volders, hOGG1326, XRCC1399 and XRCC3241 polymorphisms influence micronucleus frequencies in human lymphocytes in vivo. Mutagenesis 23, 35-41 (2008).
65. Y. C. Hong, K. H. Lee, W. C. Kim, S. K. Choi, Z. H. Woo, S. K. Shin and H. Kim, Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int. J. Cancer 116, 428-432 (2005).
66. T. Ho, G. Li, J. Lu, C. Zhao, Q. Wei and E. M. Sturgis, X-ray repair cross-complementing group 1 (XRCC1) single-nucleotide polymorphisms and the risk of salivary gland carcinomas. Cancer 110, 318-325 (2007).
67. J. Yin, U. Vogel, Y. Ma, R. Qi, Z. Sun and H. Wang, The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer 56, 153-160 (2007).
68. M. Shen, M. P. Purdue, A. Kricker, Q. Lan, A. E. Grulich, C. M. Vajdic, J. Turner, D. Whitby, S. Chanock and B. K. Armstrong, Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia. Haematologica 92, 1180-1185 (2007).
69. A. S. Andrew, H. H. Nelson, K. T. Kelsey, J. H. Moore, A. C. Meng, D. P. Casella, T. D. Tosteson, A. R. Schned and M. R. Karagas, Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 27, 1030-1037 (2006).
70. S. M. Yoon, Y. C. Hong, H. J. Park, J. E. Lee, S. Y. Kim, J. H. Kim, S. W. Lee, S. Y. Park, J. S. Lee and E. K. Choi, The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 885-891 (2005).
71. H. H. Chung, M. K. Kim, J. W. Kim, N. H. Park, Y. S. Song, S. B. Kang and H. P. Lee, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol. Oncol. 103, 1031-1037 (2006).
72. C. Li, Z. Hu, J. Lu, Z. Liu, L. E. Wang, A. K. El-Naggar, E. M. Sturgis, M. R. Spitz and Q. Wei, Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer 110, 867-875 (2007).
73. Z. Hu, H. Ma, F. Chen, Q. Wei and H. Shen, XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol. Biomarkers Prev. 14, 1810-1818 (2005).
74. C. Kiyohara, K. Takayama and Y. Nakanishi, Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 54, 267-283 (2006).
75. L. Musák, P. Vodicka, G. Klimentová, P. Soucek, M. Hánová, R. Mikulková, J. Buchancová, L. Vodicková, V. Poláková and M. Péc, Chromosomal damage and polymorphisms of DNA repair genes XRCC1 and XRCC3 in workers exposed to cytostatics. Neuro. Endocrinol. Lett. 27, 57-60 (2006).
76. E. J. Duell, J. K. Wiencke, T. J. Cheng, A. Varkonyi, Z. F. Zuo, T. D. Ashok, E. J. Mark, J. C. Wain, D. C. Christiani and K. T. Kelsey, Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human mononuclear cells. Carcinogenesis 21, 965-971 (2000).
77. J. J. Hu, T. R. Smith, M. S. Miller, H. W. Mohrenweiser, A. Golden and L. D. Case, Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22, 917-922 (2001).
78. P. E. Bonnen, P. J. Wang, M. Kimmel, R. Chakraborty and D. L. Nelson, Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12, 1846-1853 (2002).
79. A. Y. Ho, D. P. Atencio, S. Peters, R. G. Stock, S. C. Formenti, J. A. Cesaretti, S. Green, B. Haffty, K. Drumea and B. S. Rosenstein, Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int. J. Radiat. Oncol. Biol. Phys. 65, 646-655 (2006).
80. The International HapMap Consortium, A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
81. M. Baumann, T. Holscher and A. C. Begg, Towards genetic prediction of radiation responses ESTRO's GENEPI project. Radiother. Oncol. 69, 121-125 (2003).